European Regulatory Perspective on Super-Generics: Antacid Orally Disintegrating Tablets (ODT)

Authors

  • Achin jain Beloor Bayir Biotech Limited, Bangalore, India
  • Mudit Dixit Beloor Bayir Biotech Limited, Bangalore, India
  • Vasant Samaga Beloor Bayir Biotech Limited, Bangalore, India
  • B. G. Bairy Beloor Bayir Biotech Limited, Bangalore, India
  • Rohit Dixit Beloor Bayir Biotech Limited, Bangalore, India
  • M. P. Venkatesh Pharmaceutical Regulatory Affairs Group, Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Mysore, India

DOI:

https://doi.org/10.37591/tdd.v3i1.286

Abstract

Super-generic is the general form of nomenclature for hybrid medicinal product in European Union (EU). The super-generic form of the medicinal product is one that considers changes in the form of active substance, therapeutic indications, strength, pharmaceutical form or route of administration. They rely partly on results of preclinical tests and clinical trials of an innovator product and also on new data with appropriate bioavailability and bioequivalence studies. Marketing authorization for super-generics in EU can be obtained by any of the four registration processes, i.e., centralized, decentralized, mutual recognition and national procedure. Additional studies such as pharmacokinetics, preclinical and clinical studies are conducted as required by the changes that are made in the super-generic product as compared to the innovator product. Antacid orally disintegrating tablets (ODTs) as a part of super-generics have gained considerable attention since last decade. This mode of administration is expected to be beneficial to pediatric, geriatric patients or people with impaired swallowing especially psychiatric patients. These products have a significant impact on exhausting marketing authorization trend of conventional dosage forms. In an effort to develop drug products that are more convenient to use and address potential issues of patient compliance, super-generics have gained importance.

 

Keywords: super-generic, orally disintegrating tablet (ODT), antacid, patient compliance

Cite this Article

Jain A, Dixit M, Samaga Vet al. European regulatory perspective on super-generics: Antacid orally disintegrating tablets (ODT). Trends in Drug Delivery. 2016; 3(1): 31–37p

Downloads

Published

2019-02-22

Issue

Vol. 3 No. 1 (2016)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.